Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05301335 · ClinicalTrials.gov registry record · NA

Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study

A NA study of Stroke and Multiple Sclerosis, sponsored by SpineX.

Completed
Registry status
NA
Development phase
126
Enrollment target
12
Study locations

NCT05301335 is a NA study of Stroke and Multiple Sclerosis that has completed, run by SpineX. The registered enrollment target is 126 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 12 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05301335, a NA study of Stroke and Multiple Sclerosis, has completed, sponsored by SpineX.

COMPLETED
Registry status
NA
Development phase
126 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction

Interventions

  • DEVICE SCONE

Study Locations (12)

California

  • Rancho Research Institute - Downey
  • UC San Diego Health Systems - San Diego

Colorado

  • Craig Hospital - Denver

District of Columbia

  • Medstar National Rehab - Washington D.C.

Florida

  • University of Miami, Desai Sehti Urology Institute - Miami

Georgia

  • Shepherd Centre - Atlanta

Massachusetts

  • Spaulding Rehabilitation Hospital Cambridge - Cambridge

Minnesota

  • Mayo Clinic, St. Mary's Campus - Rochester

New York

  • Columbia University Irving Medical Centre - New York

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2022-05-25
Est. Completion 2024-05-01
Phase NA

Sponsor

SpineX

1 total trials

What the Registry Record Tells You About NCT05301335

The ClinicalTrials.gov registry entry for NCT05301335 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is SpineX, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which SCONE is the first listed.

NCT05301335 reports 12 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05301335 about?

NCT05301335 is a clinical study titled "Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study". The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction

What is the current status of trial NCT05301335?

This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2022-05-25. Estimated completion is 2024-05-01.

What conditions does trial NCT05301335 study?

This clinical trial studies the following conditions: Stroke, Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Injuries (Complete and Incomplete).

What interventions are being tested in trial NCT05301335?

The interventions under investigation include: SCONE (DEVICE).

Who is sponsoring clinical trial NCT05301335?

This trial is sponsored by SpineX, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05301335 being conducted?

This trial has 12 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.